Cadrenal Therapeutics' SEC filings document the regulatory record of a Nasdaq-listed, emerging-growth biopharmaceutical company focused on immune, thrombotic, and anticoagulation-related disorders. Its 8-K reports disclose financial results, Regulation FD updates, clinical and regulatory events for CAD-1005, and scientific research involving 12-lipoxygenase inhibition.
The filings also cover capital-structure activity, including common-stock registrations, at-the-market offering materials, registered direct offerings, private-placement warrants, and related material agreements. Company disclosures identify its Delaware corporate status, Nasdaq Capital Market common stock listing, governance status as an emerging growth company, and formal reporting of pipeline developments involving CAD-1005, tecarfarin, and frunexian.
Cadrenal Therapeutics, Inc. reported fourth quarter and full-year 2025 results and provided an update on its CAD-1005 program for heparin-induced thrombocytopenia (HIT). The company completed an End-of-Phase 2 FDA meeting on March 26, 2026 to align on a proposed Phase 3 pivotal trial design.
For Q4 2025, research and development expenses were $0.7 million, down from $1.5 million a year earlier, while general and administrative expenses were $2.4 million, down from $2.7 million. Cadrenal posted a quarterly net loss of $3.0 million, improving from a $4.2 million loss in Q4 2024.
For the full year 2025, operating expenses totaled $13.5 million and the net loss was $13.2 million, compared with a $10.7 million net loss in 2024. Cash and cash equivalents were $4.0 million as of December 31, 2025, and the company is evaluating financing and strategic alternatives to support planned clinical development.
Cadrenal Therapeutics reported new preclinical research on its first-in-class 12-lipoxygenase inhibitor CAD-1005, showing potential to address inflammation linked to obesity and Type 2 diabetes. In animal models, oral CAD-1005 (formerly VLX-1005) improved glycemic control, reduced pancreatic β-cell loss, lowered inflammatory cells in fat and pancreatic tissue, and decreased pro-inflammatory cytokines in adipose tissue.
The findings support 12-LOX as a key driver of obesity-related inflammation and suggest that selectively inhibiting this enzyme may help restore metabolic signaling and protect tissues from inflammatory damage. CAD-1005 is already in clinical development for suspected heparin-induced thrombocytopenia (HIT), where a Phase 2 trial showed reduced thrombotic events. The company is also advancing next-generation oral 12-LOX inhibitor CAD-2000 and maintains additional late-stage programs, including the anticoagulant tecarfarin and Factor XIa inhibitor frunexian.
Cadrenal Therapeutics reported Phase 2 trial results for CAD-1005 in heparin-induced thrombocytopenia. The randomized, blinded, placebo-controlled study did not meet its primary endpoint of improving platelet count recovery versus placebo on top of standard anticoagulant therapy. However, CAD-1005 achieved a greater than 25% absolute reduction in new or worsening thrombotic events compared with placebo, suggesting potential clinical benefit despite the small sample size. The company has been granted an End-of-Phase 2 meeting with the FDA in March 2026 to discuss a Phase 3 registration path for CAD-1005, which it describes as the only 12-LOX inhibitor in clinical development for this indication.
Cadrenal Therapeutics entered into a securities purchase agreement for a mixed stock and warrant financing. The company is selling 207,374 shares of common stock in a registered direct offering at $10.85 per share and issuing unregistered common warrants to purchase up to 414,748 additional shares in a concurrent private placement, for expected gross proceeds of about $2.2 million.
The common warrants have a $10.60 exercise price, are exercisable immediately, and will expire two years after the effective date of a future resale registration statement, with beneficial ownership capped between 4.99% and 9.99%. H.C. Wainwright & Co. is acting as placement agent, receiving cash fees, expense reimbursements, and warrants to buy 13,479 shares at $13.5625. The company, its directors, and officers agreed to 10-day lock-ups and short-term limits on new equity issuances and registration filings, plus a one-year ban on variable rate transactions other than a potential at-the-market program with Wainwright.
Cadrenal Therapeutics is issuing 207,374 shares of common stock in a registered direct offering at $10.85 per share, for gross proceeds of $2,250,007.90. In a concurrent private placement, the same investors receive unregistered common warrants to buy up to 414,748 additional shares at an exercise price of $10.60 per share.
The company expects net proceeds of approximately $1.9 million, which it plans to use for working capital and general corporate purposes. After the offering, 2,338,127 shares of common stock will be outstanding, and new investors will see immediate dilution of $8.44 per share based on an as adjusted pro forma net tangible book value of $2.41. Cadrenal also discloses that its limited capital and financing needs raise substantial doubt about its ability to continue as a going concern without further funding.
CVKD is updating its at-the-market common stock offering program under an existing shelf registration. The company has sold an aggregate of $10,005,300 of common stock through its sales agreement with H.C. Wainwright & Co. as of this prospectus supplement. This update reduces the amount available under the November 18, 2025 prospectus supplement by $2,250,007.90, leaving $569,717 of common stock that can still be sold under that supplement. CVKD’s common stock trades on the Nasdaq Capital Market under the symbol CVKD, and the last reported sale price was $11.00 per share on December 12, 2025.
Cadrenal Therapeutics, Inc. filed a prospectus supplement supporting its existing at-the-market equity program, allowing the offer and sale of up to $3,438,062 of its common stock through H.C. Wainwright & Co. as sales agent. These sales are made under an already effective Form S-3 shelf registration statement. As of the same date, the company has sold an aggregate of $9,386,964 of common stock under this at-the-market agreement. H.C. Wainwright is entitled to a 3.0% commission on the gross sales price of shares sold, and the company may suspend or terminate the program subject to the terms of the agreement.
Cadrenal Therapeutics, Inc. is updating its at-the-market equity program to offer and sell up to $3,438,062 of common stock through H.C. Wainwright & Co. as sales agent or principal. Based on an assumed price of $11.61 per share, this corresponds to up to 296,129 shares, which would raise Cadrenal’s common stock outstanding from 2,075,845 to as many as 2,371,974 shares if fully sold. Wainwright will receive a 3.0% sales commission on gross proceeds. The company plans to use any net proceeds for working capital and general corporate purposes, including potential acquisitions, licensing or investments in product candidates or other intellectual property, and possible repurchases of securities. The filing highlights that the ATM structure may lead to price variation and potential dilution for new and existing shareholders.
Cadrenal Therapeutics (CVKD) submitted an 8-K announcing it furnished a press release with financial information for the quarter ended September 30, 2025, under Item 2.02.
The company states this information, including Exhibit 99.1, is furnished and not deemed filed, and is not incorporated by reference into other SEC filings. The press release was issued on November 10, 2025.
Cadrenal Therapeutics (CVKD) reported a larger year-to-date loss and flagged liquidity risk. Net loss was $2.69 million for Q3 2025 and $10.20 million for the nine months ended September 30, 2025. Operating expenses for the nine months rose to $10.40 million, driven by higher G&A of $6.96 million (up 73%) and R&D of $3.43 million (up 29%). Interest and dividend income contributed $0.20 million year to date.
Cash and cash equivalents were $3.86 million as of September 30, 2025, after $10.03 million used in operating activities year to date. Management states these factors raise substantial doubt about the company’s ability to continue as a going concern. To bolster liquidity, Cadrenal raised $3.83 million net via its ATM during the nine months and a further approximately $0.22 million net after quarter-end.
On September 12, 2025, Cadrenal acquired eXIthera assets, including frunexian (EP-7041) and EP-7327. The company paid $50,000 at closing and expensed $151,216 in transaction costs, with contingent milestones of up to $15 million, a 2% royalty on future net sales, and 50% of royalties received under the Haisco license.